Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients

This is the first prospective study of a combination therapy involving a cardenolide and a MEK inhibitor for metastatic melanoma. Whereas BRAF mutant melanomas can exhibit profound responses to treatment with BRAF and MEK inhibitors, there are fewer options for BRAF wild-type melanomas. In preclinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankel, Arthur E., Eskiocak, Ugur, Gill, Jennifer G., Yuan, Stacy, Ramesh, Vijayashree, Froehlich, Thomas W., Ahn, Chul, Morrison, Sean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342980/
https://www.ncbi.nlm.nih.gov/pubmed/28278423
http://dx.doi.org/10.1016/j.neo.2017.01.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342980/
https://www.ncbi.nlm.nih.gov/pubmed/28278423
http://dx.doi.org/10.1016/j.neo.2017.01.010

Ejemplares similares